79754
document
Pilot study with adjuvant hormone therapy in FIGO stage I endometrial carcinoma with myometrial invasion . A pilot study with adjuvant hormone therapy in FIGO stage I endometrial carcinoma with myometrial invasion was carried out . All patients received total abdominal hysterectomy and bilateral salpingo-oophorectomy plus complementary radium therapy on the vaginal stump . After the conventional treatment , patients were randomly allocated to adjuvant hormone therapy or no further treatment . Hormone therapy consisted of gestonorone caproate ( 17 alpha-hydroxy-19-norpregn-4-en 3 , 20 dione caproate ) administered i.m . at the dose of 200 mg/week for 1 year . Of the 62 patients who entered the study , 51 were considered evaluable ( 24 with adjuvant hormone therapy and 27 with no further treatment ) . Five patients had a relapse : four of these were in the group with no further treatment . Actuarial relapse-free survival analysis at 5 years was 95.7 % in the group of adjuvant-treated patients and 82.8 % in the control group . Although there is no statistical significance , adjuvant therapy appears to result in an increase in relapse-free survival in the group of patients with deep myometrial invasion and undifferentiated carcinoma . Further studies are necessary to assess the effectiveness of hormone adjuvant treatment in FIGO stage I endometrial carcinoma with myometrial invasion .
79755
Intervention_Pharmacological
adjuvant hormone therapy
79756
Intervention_Pharmacological
adjuvant hormone therapy
79757
Intervention_Physical
total abdominal hysterectomy
79758
Intervention_Physical
bilateral salpingo-oophorectomy
79759
Intervention_Physical
complementary radium therapy on the vaginal stump
79760
Intervention_Pharmacological
adjuvant hormone therapy or no further treatment
79761
Intervention_Pharmacological
gestonorone caproate ( 17 alpha-hydroxy-19-norpregn-4-en 3 , 20 dione caproate ) administered i.m
79762
Intervention_Pharmacological
at the dose of 200 mg/week for 1 year
79763
Intervention_Pharmacological
adjuvant hormone therapy
79764
Intervention_Other
no further treatment
79765
Intervention_Pharmacological
adjuvant therapy
79766
Intervention_Pharmacological
hormone adjuvant treatment
79767
Outcome_Physical
relapse
79768
Outcome_Other
no further treatment
79769
Outcome_Mortality
Actuarial relapse-free survival
79770
Outcome_Mortality
relapse-free survival
79771
Participant_Condition
FIGO stage I endometrial carcinoma
79772
Participant_Condition
myometrial invasion
79773
Participant_Condition
FIGO stage I endometrial carcinoma
79774
Participant_Condition
myometrial invasion
79775
Participant_Sample-size
62
79776
Participant_Condition
FIGO stage I endometrial carcinoma
79777
Participant_Condition
myometrial invasion